Skip to main navigation Skip to search Skip to main content

In vivo dopamine clearance rate in rat striatum: Regulation by extracellular dopamine concentration and dopamine transporter inhibitors

Research output: Contribution to journalArticlepeer-review

101 Scopus citations

Abstract

Dopamine transporter (DAT) inhibitors are expected to decrease dopamine (DA) clearance from the extracellular space of the brain. However, mazindol and cocaine have been reported to 'anomalously' increase DA clearance rate. To better understand in vivo DAT activity both in the absence and presence of DAT inhibitors, clearance of exogenously applied DA was measured in dorsal striata of urethane-anesthetized rats using high-speed chronoamperometry. As higher amounts of DA were ejected, DA signal amplitudes, but not time courses, increased. Clearance rates increased until near maximal rates of 0.3 to 0.5 μM/s were attained. Provided baseline clearance rates were relatively low (< 0.1 μM/s), local application of either nomifensine or cocaine markedly increased exogenous DA signal amplitudes and time courses. Relative to the low baseline group, locally applied nomifensine decreased clearance rate when baseline clearance was high (~0.4 μM/s). However, even when baseline clearance rates were high, systemic injection of nomifensine mazindol, GBR 12909, or benztropine increased DA signal amplitudes to a greater extent than time courses, consistent with the observed increases n clearance rates. In contrast, despite low baseline clearance rates, systemic injection of cocaine, WIN 35,428, or d-amphetamine preferentially increased DA signal time course, consistent with the observed decreases in clearance rates. Our results emphasize that as extracellular DA concentrations increase, DAT velocity increases to a maximum, partially explaining the ability of DAT inhibitors to increase DA clearance rates. However, by itself, kinetic activation is not sufficient to explain the ability of certain systemically administered DAT inhibitors to anomalously increase DA clearance.

Original languageEnglish
Pages (from-to)266-277
Number of pages12
JournalJournal of Pharmacology and Experimental Therapeutics
Volume289
Issue number1
DOIs
StatePublished - Apr 1999

Funding

FundersFunder number
Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug AbuseR37DA004216
Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology

    Fingerprint

    Dive into the research topics of 'In vivo dopamine clearance rate in rat striatum: Regulation by extracellular dopamine concentration and dopamine transporter inhibitors'. Together they form a unique fingerprint.

    Cite this